ArticleScientific reports2025
Application of peritumoral radiomics based on simulated positioning CT images in the prognosis of intermediate-advanced esophageal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to develop a prognostic model utilizing intratumoral and peritumoral radiomics from simulated localization CT images to predict overall survival (OS) in patients with advanced esophageal cancer, while evaluating its clinical applicability. We conducted a retrospective cohort study involving 151 patients with esophageal cancer who underwent radical radiotherapy between January 2017 and January 2023 (144 men, 7 women). Participants were randomly assigned to a training cohort (n = 105) and a validation cohort (n = 46) at a 7:3 ratio. The primary outcome measured was OS. We extracted 851 radiomic features from the radiotherapy target area of localized CT images. Univariate Cox and LASSO-Cox models were employed to identify features associated with OS. We developed four Cox proportional hazards regression models: a clinical model, a GTV radiomics model combined with the clinical model, a peritumoral radiomics model combined with the clinical model, and a comprehensive radiomics-clinical model. Model performance was assessed using receiver operating characteristic (ROC) curves, Kaplan-Meier survival curves, and nomograms. The median follow-up period was 22 months (range: 6-101). The clinical model exhibited C-index values of 0.540 and 0.590 for predicting OS in the training and validation cohorts, respectively. The GTV radiomics combined with the clinical model demonstrated improved performance with C-index values of 0.753 and 0.677. The peritumoral radiomics combined with the clinical model yielded C-index values of 0.662 and 0.587. The total radiomics-clinical model showed the best predictive capability, with C-index values of 0.762 and 0.704 in the training and validation cohorts. Calibration curves validated the accuracy and clinical relevance of the total radiomics-clinical model, which effectively stratified patient risk categories (p < 0.001). The total radiomics-clinical model, developed from simulated localization CT images, demonstrates a robust ability to predict overall survival (OS) in patients with advanced esophageal cancer. By accurately identifying high- and low-risk patients, this model empowers clinicians to tailor treatment strategies to individual patient profiles. This personalized approach enhances clinical decision-making, enabling more effective allocation of resources and interventions based on the unique prognostic factors of each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.